Myebrol (BioDeep_00000009468)

   


代谢物信息卡片


1,6-DIBROMO-1,6-DIDEOXY-D-MANNITOL

化学式: C6H12Br2O4 (305.9102272)
中文名称: 1,6-二溴-1,6-二脱氧-D-甘露醇, 二溴甘露醇
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C(C(C(C(C(CBr)O)O)O)O)Br
InChI: InChI=1S/C6H12Br2O4/c7-1-3(9)5(11)6(12)4(10)2-8/h3-6,9-12H,1-2H2/t3-,4-,5-,6-/m1/s1

描述信息

L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01A - Alkylating agents
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
D009676 - Noxae > D000477 - Alkylating Agents
D000970 - Antineoplastic Agents
Same as: D02020

同义名列表

5 个代谢物同义名

1,6-DIBROMO-1,6-DIDEOXY-D-MANNITOL; mitobronitol; Myebrol; Mitobronitol; 1,6-Dibromo-1,6-dideoxy-D-mannitol



数据库引用编号

15 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Hsin Chun Tsai, Tzung Lieh Yeh, Ming Hong Hsieh, I Hui Lee, Kao Ching Chen, Po See Chen, Yen Kuang Yang, Wei Jen Yao. Association between serotonin transporter availability and overall rating scores of quality of life in healthy volunteers. Progress in neuro-psychopharmacology & biological psychiatry. 2009 Jun; 33(4):711-4. doi: 10.1016/j.pnpbp.2009.03.018. [PMID: 19332100]
  • K Paál, J Horváth, C Csáki, T Ferencz, D Schuler, J D Borsi. Effect of etoposide on the pharmacokinetics of methotrexate in vivo. Anti-cancer drugs. 1998 Oct; 9(9):765-72. doi: 10.1097/00001813-199810000-00004. [PMID: 9840721]
  • S E Kaba, A P Kyritsis, K Hess, W K Yung, R Mercier, S Dakhil, K A Jaeckle, V A Levin. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Mar; 15(3):1063-70. doi: 10.1200/jco.1997.15.3.1063. [PMID: 9060546]
  • K Paál, V Erdélyi-Tóth, E Pap, C Csáki, T Ferencz, D Schuler, J Borsi. [Pharmacokinetic study of dibromodulcitol in children with brain tumors]. Orvosi hetilap. 1994 Nov; 135(46):2527-34. doi: NULL. [PMID: 7800388]
  • C Paál, V Erdélyi-Tóth, E Pap, C Csáki, T Ferencz, D Schuler, J D Borsi. Pharmacokinetic studies on Elobromol in children with brain tumors. Anti-cancer drugs. 1994 Oct; 5(5):539-47. doi: NULL. [PMID: 7858286]
  • E Watanabe, T Shimokawa, H Yamada, H Takeyama, S Natsume, T Satake. [A case of essential thrombocythemia with clonal evolution in the terminal phase]. Gan to kagaku ryoho. Cancer & chemotherapy. 1994 Mar; 21(4):539-42. doi: . [PMID: 8129397]
  • D Schuler, P Somló, R Koóos, R Kálmánchey, E Paraicz. Treatment of malignant scala posterior brain tumors in children: the chemotherapy of relapsed medulloblastoma with a dibromdulcitol containing drug regime and pharmacokinetic studies of dibromdulcitol in children. Medical and pediatric oncology. 1992; 20(4):312-4. doi: 10.1002/mpo.2950200408. [PMID: 1608353]
  • A Wehmeier, J T Fischer, G Goerz, W Schneider. Polychemotherapy of acute myelogenous leukemia in a patient with acute intermittent porphyria. Klinische Wochenschrift. 1987 Apr; 65(7):338-40. doi: 10.1007/bf01745391. [PMID: 3473266]
  • S L Kelley, W P Peters, J Andersen, E A Furlong, E Frei, W D Henner. Pharmacokinetics of dibromodulcitol in humans: a phase I study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1986 May; 4(5):753-61. doi: 10.1200/jco.1986.4.5.753. [PMID: 3517245]
  • L H Brubaker, M O Nelson, R Birch, S Williams. Treatment of advanced adenocarcinoma of the kidney with mitolactol: a Southeastern Cancer Study Group Trial. Cancer treatment reports. 1986 Feb; 70(2):305-6. doi: NULL. [PMID: 3948194]
  • I P Horváth, J Csetényi, S Kerpel-Fronius, L Hegedüs, B Kanyár, S Eckhardt. Pharmacokinetics and metabolism of dianhydrogalactitol DAG in patients: a comparison with the human disposition of dibromodulcitol DBD. European journal of cancer & clinical oncology. 1986 Feb; 22(2):163-71. doi: 10.1016/0277-5379(86)90026-x. [PMID: 3699079]
  • J E Sokal, M Baccarani, S Tura, M Fiacchini, F Cervantes, C Rozman, G A Gomez, D A Galton, G P Canellos, T J Braun. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood. 1985 Dec; 66(6):1352-7. doi: NULL. [PMID: 3904870]
  • W D Henner, E A Furlong, S L Kelley, A Rosowsky. Assay for mitolactol and its bifunctional alkylating metabolites in plasma. Journal of pharmaceutical sciences. 1985 Sep; 74(9):983-6. doi: 10.1002/jps.2600740915. [PMID: 2999377]
  • R S Schwartz, F R Mackintosh, J Halpern, S L Schrier, P L Greenberg. Multivariate analysis of factors associated with outcome of treatment for adults with acute myelogenous leukemia. Cancer. 1984 Oct; 54(8):1672-81. doi: 10.1002/1097-0142(19841015)54:8<1672::aid-cncr2820540831>3.0.co;2-f. [PMID: 6592033]
  • J Csetényi, D Afra, S Kerpel-Fronius, I P Horváth, L Institoris, S Eckhardt. The distribution of [3H]-dibromodulcitol in the central nervous system of patients with brain tumour. European journal of cancer & clinical oncology. 1983 Oct; 19(10):1389-92. doi: 10.1016/0277-5379(93)90008-s. [PMID: 6685628]
  • K Tóth, J Sugár, S Somfai-Relle, L Hedegüs. Mutagenicity of dibromodulcitol (DBD), an alkylating anticancer drug) and its mono- and bifunctional conversion products studied by the Salmonella/microsome assay. Carcinogenesis. 1982; 3(3):333-6. doi: 10.1093/carcin/3.3.333. [PMID: 7044598]
  • N E Mischler, D C Tormey, J Klotz, E C Borden, G Ramirez, T K Banerjee, R M Carr, S D Zaentz, J Graf. Phase II study of dibromodulcitol in colorectal, kidney, and other carcinomas. Cancer clinical trials. 1981; 4(4):407-10. doi: NULL. [PMID: 7318122]
  • E Nissen, R Dettmer, D Fiedler, M Bodammer. [Polyamines and their significance for control of cancer chemotherapy (author's transl)]. Archiv fur Geschwulstforschung. 1980; 50(4):336-40. doi: NULL. [PMID: 7458581]
  • I P Horváth, J Csetényi, S Kerpel-Fronius, I Hindy, S Eckhardt. Metabolism and pharmacokinetics of dibromodulcitol (DBD, NSC-104800) in man. I. Metabolites of DBD. European journal of cancer. 1979 Mar; 15(3):337-44. doi: 10.1016/0014-2964(79)90045-8. [PMID: 446515]
  • L Berek, S Bános, I Szeri, P Anderlik, K Aszódi. Bone changes in young mice with impaired lymphoid system. Acta microbiologica Academiae Scientiarum Hungaricae. 1975; 22(1):1-8. doi: NULL. [PMID: 1089352]
  • L INSTITORIS, I P HORVATH, E CSANYI. STUDY ON THE DISTRIBUTION AND METABOLISM OF 82BR-LABELLED DIBROMOMANNITOL (DBM) IN NORMAL AND TUMOR-BEARING RATS. Neoplasma. 1964; 11(?):245-55. doi: NULL. [PMID: 14171419]